Abstract:A license, in the context of a patent, stands for a contract by which the licensor (patentee) authorizes the licensee to exercise defined rights over the patent. The effect is to give to the licensee a right to do what he/she would otherwise be prohibited from doing. A license may be voluntary or compulsory.Compulsory licensing has been defined to be a governmental grant to someone to produce a patented product without having the patent- holder's consent . It is a balance between the needs of technology consumers and producers- between a governmental grant and preservation of patent holder rights . It implies a waiver to patents, at least during the persistence of a crisis and can step in whenever there is a potential conflict- for instance between health and medical patents rendering the availability of some medicine scarce due to an exclusive right or an extremely high price.Under a compulsory license, the licensee is per force required to offer his intellectual property for a predetermined royalty or for a royalty to be decided by the authority on a case to case basis. The provisions for grant of compulsory license are aimed at making best use of the patented invention - not to restrict the rights of the patentee, but to stop abuse and misuse and to safeguard the interests of the public. Public health principles, in the context of access to medicines, are supported by a range of national and international legal and policy instruments. The TRIPS agreement is a milestone in this. It provides patent protection, for a minimum of 20 years, for products in almost all fields of technology including pharmaceuticals. One of the most debated provisions of the TRIPS Agreement is compulsory licensing, its meaning, purpose and application. Article 31 of the TRIPS Agreement, read along with the Paris Convention and Doha Declaration on Public Health and the August 2003 Waiver Decision of the WTO (concerning the para 6 mechanism) largely govern the international legal regime concerning ‘use without authorization’ of the right holder. Although not specifically worded, it includes compulsory licenses in the public interest as a judicial remedy and for government use of patented inventions. It is also worth mentioning here that many countries have historically allowed ‘use without authorization’ within their patent laws - for causing general inconvenience, affecting trade, unreasonable prices or for nonlocal ‘working’ among other reasons – or under the competition law regime – for abuse of patent rights which may be price related or otherwise. However TRIPS does not specify grounds for the issue of compulsory licenses but does prescribe conditions for grant and use. The WTO members are left with considerable leeway in providing in their national laws grounds concerning compulsory licenses. Many developing countries have issued compulsory licenses in the post- TRIPS context primarily to address public health concerns.The study examines the pros and cons of compulsory licensing as a possible way for developing countries to overcome patent protection and in that way facilitate - among other things- access to drugs at affordable prices especially in the backdrop of the pandemic. The hypothesis “Compulsory licensing of essential drugs/vaccines in the backdrop of the COVID-19 pandemic will only backfire and cannot be a panacea to achieve the felt need of increasing production of essential drugs/vaccines to meet the surging demand “ is proved statistically. The paper concludes with the finding that the best course would be to embark on a path of voluntary licenses and that any exercise of statutory powers can only prove to be counter-productive at this stage.

The effect of insulin on the glycogenolytic cascade and on the activity of glycogen synthase in the liver of anaesthetized rabbits.

Licensing Strategies in the Presence of Patent Thickets

Patent Dependency Under European and European Union Patent Law – a Regulatory Gap

Reductionist Intellectual Property Protection and Expansionist (and “Prodevelopment”) Competition Rules as a Human Rights Imperative? Enhancing Technology Transfer to the Global South

Price Versus Market Share with Royalty Licensing: Incomplete Adoption of a Superior Technology with Heterogeneous Firms

The Simple Math of Royalties and Drug Competition During the 180-Day Generic Exclusivity Period

Tailoring the Patent System to Work for Software and Technology Patents

Revision Total Knee Arthroplasty with a Cemented Posterior Stabilized, Condylar Constrained or Fully Constrained Prosthesis: A Minimum 2-year Follow-up Analysis

Exploiting treaty ambiguity: Public health exceptions in the WTO TRIPS agreement

Optimal patent licensing: from three to two part tariffs

Licensing standard‐essential patents with costly enforcement

From TRIPS to FTAs and Back: Re-Conceptualising the Role of a Multilateral IP Framework in a TRIPS-Plus World

Strategic Delegation And Licensing Of Patented Technology Under To Fixed Fee Schedule

COVID-19 Pandemic: Should Nations Resort to Compulsory Licensing of Drugs and Vaccines? An Analysis of the Effect of Such Pervasive Steps and Non-Market Price-Setting on the Economics and Political Economy of Creative Industries

'What Exactly Are You Implying?': The Elusive Nature of the Implied Copyright License

Trade-Related Aspects of Intellectual Property Rights Waiver at the World Trade Organization: A BIT of a Challenge

Technology Strategy Revealed: Patterns and Influences of Patent-Licensing Behaviour in Japanese Firms.

Technology royalty as a strategic impetus in knowledge exchange

Network Effects and Technology Licensing with Fixed Fee, Royalty, and Hybrid Contracts

The Smartphone Royalty Stack: Surveying Royalty Demands for the Components Within Modern Smartphones

The Pro-Patent Holder Approach in Unwired V. Huawei in Interpreting the ‘Fair, Reasonable and Non- Discriminatory’ Rule for the Licensing of Standard Essential Patents